We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | -2.64% | 1.475 | 1.45 | 1.50 | 1.47 | 1.448 | 1.45 | 2,259,529 | 16:35:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -3.98M | -0.0035 | -4.20 | 16.79M |
From May 2023 to May 2024
By Anthony O. Goriainoff
Hemogenyx Pharmaceuticals said the U.S. Food and Drug Administration has accepted its plans to address the agency's concerns over its leukemia treatment product candidate.
The London-listed biopharmaceutical group--that develops new therapies and treatments for blood diseases--said Thursday it had submitted a detailed plan for its HEMO-CAR-T investigational new drug, or IND, which was supported by laboratory tests to address the FDA's concerns.
On July 10, the company said the FDA was concerned with the splicing that occurs during the manufacturing of the lentivirus used in its acute myeloid leukemia treatment product.
"We are now working hard to complete the schedule of work set out in the plan and to resubmit the IND as expeditiously as possible in order to move forward with clinical trials of HEMO-CAR-T," Chief Executive Vladislav Sandler said.
Shares at 0734 GMT were up 0.02 pence, or 1.5%, at 1.68 pence.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 14, 2023 03:56 ET (07:56 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Hemogenyx Pharmaceuticals Chart |
1 Month Hemogenyx Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
